查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1532591

溶瘤病毒治疗市场 - 病毒类型（基因工程溶瘤、溶瘤野生型）、应用（实体瘤、黑色素瘤）、最终用户（医院、专科诊所、癌症研究机构） - 全球预测（2024 - 2032）

Oncolytic Virotherapy Market - Virus Type (Genetically Engineered Oncolytic, Oncolytic Wild-type), Application (Solid Tumors, Melanoma), End user (Hospitals, Specialty Clinics, Cancer Research Institutes) - Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 125 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球溶瘤病毒治疗市场在 2024 年至 2032 年期间将成长 26.9%，这归因于癌症研究投资的不断增加，加速了创新疗法的发现和发展。这些投资支持广泛的临床前和临床研究，以优化溶瘤病毒的功效和安全性，促进标靶癌症治疗的突破。增加的资金也支持联合疗法的开发，将溶瘤病毒疗法与免疫疗法等其他方式结合，以改善患者的治疗效果。此外，研发的增加促进了生物技术公司、研究机构和製药公司之间的合作，推动有效溶瘤病毒治疗解决方案的商业化，并将其扩展到更广泛的患者群体。

举例来说，2023 年 9 月，美国联邦政府宣布计划投资近 1.15 亿美元用于三个大学项目，旨在发现检测和对抗癌症的新方法。作为拜登政府癌症登月计画的一部分，这些计画透过与卫生高级研究计画局 (ARPA-H) 达成的协议获得资助。这些研究中心将由密苏里大学、莱斯大学和乔治亚理工学院领导。 ARPA-H 在癌症研究领域处于领先地位，支持政府在 25 年内将癌症死亡率降低一半的宏伟目标。

整个溶瘤病毒疗法市场根据病毒类型、应用、最终用途和地区进行分类。

溶瘤野生型病毒部分将在 2024 年至 2032 年期间取得显着进展。使用水泡性口炎病毒、新城疫病毒和呼肠孤病毒等野生型病毒的溶瘤病毒疗法正受到关注，因为它们具有选择性感染和破坏癌细胞同时不伤害健康组织的自然能力。这些病毒可以有效引发针对肿瘤的免疫反应，并增强人体的自然防御能力。它们固有的溶瘤特性与基因工程的进步一致，使研究人员能够提高其功效和安全性。因此，这些溶瘤野生型病毒正在成为开发创新癌症疗法的有希望的候选者，推动了对该领域的巨大兴趣和投资。

到 2032 年，在溶瘤病毒学解决传统治疗限制的潜力的推动下，黑色素瘤细分市场将占据相当大的溶瘤病毒学市场。溶瘤病毒疗法提供了一种有针对性的方法，特别是感染和杀死黑色素瘤细胞，同时保护健康组织。它能够诱导针对肿瘤的强大免疫反应，从而提高整体治疗效果。此外，溶瘤病毒工程的最新进展提高了安全性和有效性，使其成为抗药性或晚期黑色素瘤患者的一个有前途的选择。这种创新疗法符合肿瘤学中对更有效、个人化治疗策略的需求，促进了其在黑色素瘤护理中的采用。

由于对创新癌症治疗的大力关注以及对研发的大量投资，欧洲溶瘤病毒学市场正在蓬勃发展。欧洲国家正积极支持溶瘤病毒疗法的临床试验和监管途径，为市场成长创造有利的环境。此外，生物技术公司、研究机构和医疗保健提供者之间的合作不断增加，以及对标靶癌症治疗的需求不断增长，推动了溶瘤病毒学解决方案在整个地区的扩展。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症发生率上升
      • 越来越多人批准溶瘤疗法治疗罕见的癌症
      • 增加开发新溶瘤病毒疗法的投资
      • 越来越关注联合疗法
    • 产业陷阱与挑战
      • 与临床级溶瘤病毒放大相关的问题
      • 临床研究需要高额投资
  • 成长潜力分析
  • 未来市场趋势
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按病毒类型，2021 - 2032 年

  • 主要趋势
  • 基因工程溶瘤病毒
    • 腺病毒
    • 单纯疱疹病毒
    • 牛痘病毒
  • 溶瘤野生型病毒
    • 呼肠孤病毒
    • 水泡性口炎病毒
    • 新城疫病毒

第 6 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 实体肿瘤
    • 乳癌
    • 摄护腺癌
    • 肺癌
    • 胶质母细胞瘤
  • 黑色素瘤
    • 白血病
    • 淋巴瘤
    • 骨髓瘤
    • 血液系统恶性肿瘤

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 癌症研究机构

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Amgen Inc.
  • BioVex, Inc.
  • Circio Holding ASA
  • Daiichi Sankyo Company
  • DNAtrix
  • Lokon Pharma AB
  • Medigene AG
  • Oncolytics Biotech Inc.
  • PsiOxus Therapeutics
  • Shanghai Sunway Biotech Co., Ltd.
  • SillaJen, Inc.
  • Sorrento Therapeutics
  • Theriva Biologics
  • Transgene SA
  • Virogin Biotech
简介目录
Product Code: 9645

Global Oncolytic Virotherapy Market will expand at 26.9% throughout 2024-2032, attributed to growing investments in cancer research accelerating the discovery and development of innovative treatments. These investments enable extensive preclinical and clinical studies to optimize the efficacy and safety of oncolytic viruses, fostering breakthroughs in targeted cancer therapy. Enhanced funding also supports the development of combination therapies, integrating oncolytic virotherapy with other modalities like immunotherapy to improve patient outcomes. Additionally, increased R&D facilitates collaboration between biotech companies, research institutions, and pharmaceutical firms, driving the commercialization of effective oncolytic virotherapy solutions and expanding their availability to a broader patient population.

Citing an instance, in September 2023, the U.S. federal government announced plans to invest nearly $115 million in three university-based projects aimed at discovering new methods to detect and combat cancer. These projects are funded through agreements with the Advanced Research Projects Agency for Health (ARPA-H) as part of the Biden administration's Cancer Moonshot initiative. The research centers will be led by the University of Missouri, Rice University, and the Georgia Institute of Technology. ARPA-H is leading the way in pioneering cancer research, supporting the Administration's ambitious goal to halve the cancer death rate within 25 years.

The overall oncolytic virotherapy market is categorized based on virus type, application, end use, and region.

The oncolytic wild-type viruses segment will amass significant gains over 2024-2032. Oncolytic virotherapy using wild-type viruses like vesicular stomatitis virus, Newcastle disease virus, and reovirus is gaining traction due to their natural ability to selectively infect and destroy cancer cells while sparing healthy tissue. These viruses can effectively trigger immune responses against tumors, enhancing the body's natural defenses. Their inherent oncolytic properties, in line with advancements in genetic engineering, enable researchers to improve their efficacy and safety profiles. As a result, these oncolytic wild-type viruses are becoming promising candidates in the development of innovative cancer therapies, driving significant interest and investment in the field.

The Melanoma segment will capture a decent oncolytic virology market share by 2032, driven by the potential of oncolytic virology to address the limitations of traditional treatments. Oncolytic virotherapy offers a targeted approach, specifically infecting and killing melanoma cells while sparing healthy tissue. Its ability to induce a robust immune response against tumors enhances overall treatment efficacy. Additionally, recent advancements in oncolytic virus engineering improve safety and effectiveness, making it a promising option for patients with resistant or advanced melanoma. This innovative therapy aligns with the need for more effective, personalized treatment strategies in oncology, boosting its adoption in melanoma care.

Europe oncolytic virology market is thriving due to a robust focus on innovative cancer treatments and substantial investment in research and development. European countries are actively supporting clinical trials and regulatory pathways for oncolytic virotherapy, fostering a favorable environment for market growth. Additionally, increasing collaborations between biotech firms, research institutions, and healthcare providers, along with rising demand for targeted cancer therapies, drive the expansion of oncolytic virology solutions across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of cancer
      • 3.2.1.2 Growing approvals for oncolytic therapy for treating rare cancers
      • 3.2.1.3 Increasing investments for developing new oncolytic virotherapies
      • 3.2.1.4 Growing focus towards combination therapies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Issues related to scaling-up of clinical-grade oncolytic viruses
      • 3.2.2.2 Requirement for high investments in clinical research
  • 3.3 Growth potential analysis
  • 3.4 Future market trends
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Virus Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Genetically engineered oncolytic viruses
    • 5.2.1 Adenovirus
    • 5.2.2 Herpes simplex virus
    • 5.2.3 Vaccinia virus
  • 5.3 Oncolytic wild-type viruses
    • 5.3.1 Reovirus
    • 5.3.2 Vesicular stomatitis virus
    • 5.3.3 Newcastle disease virus

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Solid tumors
    • 6.2.1 Breast cancer
    • 6.2.2 Prostate cancer
    • 6.2.3 Lung cancer
    • 6.2.4 Glioblastoma
  • 6.3 Melanoma
    • 6.3.1 Leukemia
    • 6.3.2 Lymphoma
    • 6.3.3 Myeloma
    • 6.3.4 Hematological malignancies

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Amgen Inc.
  • 9.2 BioVex, Inc.
  • 9.3 Circio Holding ASA
  • 9.4 Daiichi Sankyo Company
  • 9.5 DNAtrix
  • 9.6 Lokon Pharma AB
  • 9.7 Medigene AG
  • 9.8 Oncolytics Biotech Inc.
  • 9.9 PsiOxus Therapeutics
  • 9.10 Shanghai Sunway Biotech Co., Ltd.
  • 9.11 SillaJen, Inc.
  • 9.12 Sorrento Therapeutics
  • 9.13 Theriva Biologics
  • 9.14 Transgene SA
  • 9.15 Virogin Biotech